Astra gives as well as taking away

Data Insights

Since Pascal Soriot took the helm of AstraZeneca in October 2012 he has made his name as one of the industry’s most active asset buyers. But on his watch Astra has also done more than its share of divestments, though with somewhat less fanfare.

Yesterday’s sale of US Entocort rights to Perrigo was the latest in a string of transactions to rid Astra’s portfolio of assets that do not quite fit, and investment bankers should remember that there is significant business to be had here. Over the past three years Astra’s divestments have brought in more than $1bn of deals per annum (see table below).

And that total value – $3.2bn over three years – comprises only those deals whose financial terms have been disclosed. The list includes not only areas on which Astra has clearly given up but also projects in red-hot areas in which a niche exists where the UK group realises it cannot be a leader.

The best example is the anti-PD-L1 MAb durvalumab, which was licensed to Celgene for $450m up front – specifically for haematological malignancies. Durvalumab is one of Astra’s most important R&D prospects, but the group has been smart in realising that it cannot compete with Celgene’s lead in blood cancers, and could get a decent chunk of money in return.

Non-core

Yesterday’s US deal with Perrigo completed the unloading of Entocort, the Crohn’s disease drug that Astra had earlier sold ex-US to Tillotts Pharma, a unit of Zeria Pharmaceutical.

This closes the book on a non-core, off-patent drug for which Astra has received an immediate $595m combined – a sum not to be sniffed at, even in these days of cheap debt. Along the theme of ridding itself of non-core assets Astra sold OTC brands to Genomma and Myalept to Aegerion, though financials were not disclosed.

The sale of Caprelsa to Sanofi looks more like Astra being offered a price it could not turn down, oncology clearly not being non-core (Sanofi sees promise in Astra’s unwanted orphan Caprelsa, July 27, 2015).

Astra's divestments on Pascal Soriot's watch
Company Asset Deal value* ($m) Deal date
Ironwood Pharmaceuticals Nexium Oct 2012
Par/Endo International Candesartan & hydrochlorothiazide Dec 2012
Pierre Fabre Zoladex Dec 2012
Navidea Biopharmaceuticals AZD2184 & AZD2995 Jan 2013
Allergan Rosuvastatin Mar 2013
Kolltan Pharmaceuticals KTN3379 Jul 2013
Genomma Lab  OTC brands Sep-13
Horizon Pharma Vimovo 35 Nov 2013
Ono Pharmaceutical Forxiga Dec 2013
Cancer Research Technology AZD2098 Dec 2013
Clinigen Group Ethyol Aug 2014
IGI Laboratories  18 products 10 Sep 2014
Lilly AZD3293/ LY3314814 500 Sep 2014
Aegerion Pharmaceuticals Myalept Jan 2015
Hutchison China Meditech Seroquel Jan 2015
Daiichi Sankyo Movantik 825 Mar 2015
Ardelyx NHE3 inhibitors 15 Jun-15
Celgene Durvalumab 450 Apr 2015
Zeria Pharmaceutical Entocort 215 Jul 2015
Sanofi Caprelsa 300 Jul 2015
Daiichi Sankyo FluMist Quadrivalent Sep 2015
Valeant Brodalumab 445 Sep 2015
Perrigo Entocort 380 Oct 2015
Note: *combined terms, where disclosed.

Excluded from the list is last week’s swap deal with Sanofi over 200,000 compounds, which rather than being a divestment looks like a novel drug discovery tie-up. This seems similar to Astra’s 2013 alliance with Cancer Research UK to study AZD2098, a project originally designed for asthma, in renal cancer.

Mr Soriot’s list will interest those under the impression that Astra has just been boldly buying a pipeline through transactions like the mRNA deal with Moderna worth $240m up front – one of the first defining moves of Mr Soriot’s stewardship. Other prominent buys include Almirall’s respiratory business for an initial $875m, and Innate Pharma’s IPH2201, licensed in for $250m up front.

But obvious themes emerge among the divestments. One is what Astra considers non-core, such as the high-risk area of Alzheimer’s, as evidenced by transactions with Navidea on two beta-amlyoid imaging agents and with Lilly on a BACE inhibitor.

Any deal bankers pitching for business should take a good look at what else is in Astra’s portfolio; if the price is right the group will deal.

To contact the writers of this story email Jacob Plieth or Edwin Elmhirst in London at news@epvantage.com or follow @JacobPlieth or @EPVantage on Twitter

Share This Article